title: [Clinical study of rhIL-11 for prevention and treatment of chemotherapy-induced thrombocytopenia].
abstract: OBJECTIVE
  Cancer chemotherapy can induce thrombocytopenia. It is necessory to develop drugs that can prevent and treat thrombocytopenia. The current study was designed to evaluate the efficacy and toxicity of rhIL-11 in prevention and treatment of chemotherapy-induced thrombocytopenia.
  
  
  METHODS
  A total of 109 cancer patients were involved randomly into AB or BA group and every patient received 2 cycles of chemotherapy. IL-11 was administered subcutaneously(50 micrograms/kg/d), beginning 24 hours after completion of chemotherapy for 14 consecutive days or continuing until platelet count was > 400 x 10(9)/L during cycle A. Patients did not received IL-11 during cycle B. Another 41 cases of cancer patients whose platelet were less than 50 x 10(9)/L after chemotherapy entered into open study group. IL-11 administration was the same as above.
  
  
  RESULTS
  Efficacy can be evaluated in 107 cases in controlled study group. Mean platelet count of cycle A was (246.49 +/- 88.64) x 10(9)/L and cycle B was (180.24 +/- 83.34) x 10(9)/L(P = 0.000). Grade III/IV thrombocytopenia in cycle A and cycle B were 7/107(6.5%) and 15/107(14%), respectively (P = 0.04). The minimum platelet counts were (136.46 +/- 74.64) x 10(9)/L and (107.77 +/- 61.33) x 10(9)/L, respectively (P = 0.000). The maximum platelet counts were (381.28 +/- 150.39) x 10(9)/L and (207.44 +/- 113.32) x 10(9)/L, respectively (P = 0.000). For open study group, 32 patients could be evaluated. The platelet count increased from(30.1875 +/- 12.13) x 10(9)/L to (226.25 +/- 163.91) x 10(9)/L after IL-11 administration. Major adverse effects were edema, dizziness, palpitation, etc.
  
  
  CONCLUSIONS
  rhIL-11 can reduce thrombocytopenia induced by chemotherapy and is a safe and effective drug for treatment of thrombocytopenia.
authors.affiliation: Cancer Center, Sun Yat-sen University, Guangzhou 510060, P. R. China. zsesun@21cn.com
authors.forename: Xiao-fei
authors.initials: XF
authors.lastname: Sun
authors.forename: Zhong-zhen
authors.initials: ZZ
authors.lastname: Guan
authors.forename: He
authors.initials: H
authors.lastname: Huang
authors.forename: Qing-hua
authors.initials: QH
authors.lastname: Zhou
authors.forename: Cheng
authors.initials: C
authors.lastname: Yi
authors.forename: Li-jian
authors.initials: LJ
authors.lastname: Zhang
authors.forename: Jun
authors.initials: J
authors.lastname: Zhu
authors.forename: Rong
authors.initials: R
authors.lastname: Li
authors.forename: Juan
authors.initials: J
authors.lastname: Zhou
authors.forename: Mei
authors.initials: M
authors.lastname: Zhang
authors.forename: Yin
authors.initials: Y
authors.lastname: Guo
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004244:Dizziness / Q000139:chemically induced; D004487:Edema / Q000139:chemically induced; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D006801:Humans; D017370:Interleukin-11 / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy*; D010976:Platelet Count; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D017370:Interleukin-11; D011994:Recombinant Proteins